Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Improved process conditions for increasing expression of MHC class II protein from a stable Drosophila S2 cell line.

Shen X, Dojcinovic D, Baldi L, Hacker DL, Luescher IF, Wurm FM.

Biotechnol Lett. 2018 Jan;40(1):85-92. doi: 10.1007/s10529-017-2440-0. Epub 2017 Oct 9.

PMID:
28993910
2.

In silico and cell-based analyses reveal strong divergence between prediction and observation of T-cell-recognized tumor antigen T-cell epitopes.

Schmidt J, Guillaume P, Dojcinovic D, Karbach J, Coukos G, Luescher I.

J Biol Chem. 2017 Jul 14;292(28):11840-11849. doi: 10.1074/jbc.M117.789511. Epub 2017 May 23.

3.

Vaccination with LAG-3Ig (IMP321) and Peptides Induces Specific CD4 and CD8 T-Cell Responses in Metastatic Melanoma Patients--Report of a Phase I/IIa Clinical Trial.

Legat A, Maby-El Hajjami H, Baumgaertner P, Cagnon L, Abed Maillard S, Geldhof C, Iancu EM, Lebon L, Guillaume P, Dojcinovic D, Michielin O, Romano E, Berthod G, Rimoldi D, Triebel F, Luescher I, Rufer N, Speiser DE.

Clin Cancer Res. 2016 Mar 15;22(6):1330-40. doi: 10.1158/1078-0432.CCR-15-1212. Epub 2015 Oct 23.

4.

Corrigendum: the antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini AA, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L.

Nat Commun. 2015 Mar 11;6:6595. doi: 10.1038/ncomms7595. No abstract available.

5.

The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis.

Lande R, Botti E, Jandus C, Dojcinovic D, Fanelli G, Conrad C, Chamilos G, Feldmeyer L, Marinari B, Chon S, Vence L, Riccieri V, Guillaume P, Navarini AA, Romero P, Costanzo A, Piccolella E, Gilliet M, Frasca L.

Nat Commun. 2014 Dec 3;5:5621. doi: 10.1038/ncomms6621. Erratum in: Nat Commun. 2015;6:6595.

PMID:
25470744
6.

Analysis, Isolation, and Activation of Antigen-Specific CD4(+) and CD8(+) T Cells by Soluble MHC-Peptide Complexes.

Schmidt J, Dojcinovic D, Guillaume P, Luescher I.

Front Immunol. 2013 Jul 30;4:218. doi: 10.3389/fimmu.2013.00218. eCollection 2013.

7.

MHC class II/ESO tetramer-based generation of in vitro primed anti-tumor T-helper lines for adoptive cell therapy of cancer.

Poli C, Raffin C, Dojcinovic D, Luescher I, Ayyoub M, Valmori D.

Haematologica. 2013 Feb;98(2):316-22. doi: 10.3324/haematol.2012.071712. Epub 2012 Aug 8.

8.

NY-ESO-1-specific circulating CD4+ T cells in ovarian cancer patients are prevalently T(H)1 type cells undetectable in the CD25+ FOXP3+ Treg compartment.

Redjimi N, Duperrier-Amouriaux K, Raimbaud I, Luescher I, Dojcinovic D, Classe JM, Berton-Rigaud D, Frenel JS, Bourbouloux E, Valmori D, Ayyoub M.

PLoS One. 2011;6(7):e22845. doi: 10.1371/journal.pone.0022845. Epub 2011 Jul 29.

9.

MAGE-A3 and MAGE-A4 specific CD4(+) T cells in head and neck cancer patients: detection of naturally acquired responses and identification of new epitopes.

Cesson V, Rivals JP, Escher A, Piotet E, Thielemans K, Posevitz V, Dojcinovic D, Monnier P, Speiser D, Bron L, Romero P.

Cancer Immunol Immunother. 2011 Jan;60(1):23-35. doi: 10.1007/s00262-010-0916-z. Epub 2010 Sep 21.

PMID:
20857101
10.

Assessment of vaccine-induced CD4 T cell responses to the 119-143 immunodominant region of the tumor-specific antigen NY-ESO-1 using DRB1*0101 tetramers.

Ayyoub M, Pignon P, Dojcinovic D, Raimbaud I, Old LJ, Luescher I, Valmori D.

Clin Cancer Res. 2010 Sep 15;16(18):4607-15. doi: 10.1158/1078-0432.CCR-10-1485. Epub 2010 Jul 29.

11.

Monitoring of NY-ESO-1 specific CD4+ T cells using molecularly defined MHC class II/His-tag-peptide tetramers.

Ayyoub M, Dojcinovic D, Pignon P, Raimbaud I, Schmidt J, Luescher I, Valmori D.

Proc Natl Acad Sci U S A. 2010 Apr 20;107(16):7437-42. doi: 10.1073/pnas.1001322107. Epub 2010 Apr 5.

12.

Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.

Jandus C, Bioley G, Dojcinovic D, Derré L, Baitsch L, Wieckowski S, Rufer N, Kwok WW, Tiercy JM, Luescher IF, Speiser DE, Romero P.

Cancer Res. 2009 Oct 15;69(20):8085-93. doi: 10.1158/0008-5472.CAN-09-2226. Epub 2009 Oct 6.

13.
14.

Increased mobility of major histocompatibility complex I-peptide complexes decreases the sensitivity of antigen recognition.

Segura JM, Guillaume P, Mark S, Dojcinovic D, Johannsen A, Bosshard G, Angelov G, Legler DF, Vogel H, Luescher IF.

J Biol Chem. 2008 Aug 29;283(35):24254-63. doi: 10.1074/jbc.M803549200. Epub 2008 Jun 25.

15.

Soluble MHC-peptide complexes containing long rigid linkers abolish CTL-mediated cytotoxicity.

Angelov GS, Guillaume P, Cebecauer M, Bosshard G, Dojcinovic D, Baumgaertner P, Luescher IF.

J Immunol. 2006 Mar 15;176(6):3356-65.

16.

Identification of a region of the Arabidopsis AtAOX1a promoter necessary for mitochondrial retrograde regulation of expression.

Dojcinovic D, Krosting J, Harris AJ, Wagner DJ, Rhoads DM.

Plant Mol Biol. 2005 May;58(2):159-75.

PMID:
16027972

Supplemental Content

Loading ...
Support Center